BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 11398877)

  • 1. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
    Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
    Kelly K; Lovato L; Bunn PA; Livingston RB; Zangmeister J; Taylor SA; Roychowdhury D; Crowley JJ; Gandara DR;
    Clin Cancer Res; 2001 Aug; 7(8):2325-9. PubMed ID: 11489808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
    Hanna N; Bunn PA; Langer C; Einhorn L; Guthrie T; Beck T; Ansari R; Ellis P; Byrne M; Morrison M; Hariharan S; Wang B; Sandler A
    J Clin Oncol; 2006 May; 24(13):2038-43. PubMed ID: 16648503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.
    Dowlati A; Crosby L; Remick SC; Makkar V; Levitan N
    Lung Cancer; 2001 May; 32(2):155-62. PubMed ID: 11325486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
    Mavroudis D; Veslemes M; Kouroussis Ch; Tzanakis N; Ferdoutsis E; Toumbis M; Ziotopoulos P; Agelidou M; Tselepatiotis E; Kalbakis K; Souglakos J; Magkanas E; Samonis G; Georgoulias V;
    Lung Cancer; 2002 Oct; 38(1):59-63. PubMed ID: 12367794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
    Kakolyris S; Agelidou A; Androulakis N; Tsaroucha E; Kouroussis Ch; Agelidou M; Karvounis N; Veslemes M; Christophylakis Ch; Argyraki A; Geroyianni A; Georgoulias V
    Lung Cancer; 2006 Jul; 53(1):59-65. PubMed ID: 16716447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
    Ignatiadis M; Mavroudis D; Veslemes M; Boukovinas J; Syrigos K; Agelidou M; Agelidou A; Gerogianni A; Pavlakou G; Tselepatiotis E; Nikolakopoulos J; Georgoulias V
    Clin Lung Cancer; 2005 Nov; 7(3):183-9. PubMed ID: 16354313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
    Niell HB; Herndon JE; Miller AA; Watson DM; Sandler AB; Kelly K; Marks RS; Perry MC; Ansari RH; Otterson G; Ellerton J; Vokes EE; Green MR;
    J Clin Oncol; 2005 Jun; 23(16):3752-9. PubMed ID: 15923572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
    Oh IJ; Kim KS; Park CK; Kim YC; Lee KH; Jeong JH; Kim SY; Lee JE; Shin KC; Jang TW; Lee HK; Lee KY; Lee SY
    BMC Cancer; 2016 Aug; 16(1):690. PubMed ID: 27566413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
    Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
    J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
    Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
    Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
    Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study.
    Bunn PA; Kelly K
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):11-5. PubMed ID: 9007114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
    Bunn PA; Kelly K
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-144-S12-148. PubMed ID: 9331140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
    Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L
    Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.